Wen Jingran, Scoles Daniel R, Facelli Julio C
Department of Biomedical Informatics, University of Utah, Salt Lake City, Utah, United States of America.
Department of Neurology, University of Utah, Salt Lake City, Utah, United States of America.
PLoS One. 2017 May 25;12(5):e0178333. doi: 10.1371/journal.pone.0178333. eCollection 2017.
Protein misfolding and aggregation is a pathogenic feature shared among at least ten polyglutamine (polyQ) neurodegenerative diseases. While solvent-solution interaction is a key factor driving protein folding and aggregation, the solvation properties of expanded polyQ tracts are not well understood. By using GPU-enabled all-atom molecular dynamics simulations of polyQ monomers in an explicit solvent environment, this study shows that solvent-polyQ interaction propensity decreases as the lengths of polyQ tract increases. This study finds a predominance in long-distance interactions between residues far apart in polyQ sequences with longer polyQ segments, that leads to significant conformational differences. This study also indicates that large loops, comprised of parallel β-structures, appear in long polyQ tracts and present new aggregation building blocks with aggregation driven by long-distance intra-polyQ interactions. Finally, consistent with previous observations using coarse-grain simulations, this study demonstrates that there is a gain in the aggregation propensity with increased polyQ length, and that this gain is correlated with decreasing ability of solvent-polyQ interaction. These results suggest the modulation of solvent-polyQ interactions as a possible therapeutic strategy for treating polyQ diseases.
蛋白质错误折叠和聚集是至少十种聚谷氨酰胺(polyQ)神经退行性疾病共有的致病特征。虽然溶剂 - 溶液相互作用是驱动蛋白质折叠和聚集的关键因素,但对于扩展的聚谷氨酰胺链段的溶剂化性质却了解甚少。通过在明确的溶剂环境中对聚谷氨酰胺单体进行基于GPU的全原子分子动力学模拟,本研究表明,随着聚谷氨酰胺链段长度的增加,溶剂与聚谷氨酰胺的相互作用倾向降低。本研究发现,在具有较长聚谷氨酰胺片段的聚谷氨酰胺序列中,相距较远的残基之间存在远距离相互作用占主导地位,这导致了显著的构象差异。本研究还表明,由平行β结构组成的大环出现在长聚谷氨酰胺链段中,并呈现出由聚谷氨酰胺内远距离相互作用驱动聚集的新聚集构建块。最后,与之前使用粗粒度模拟的观察结果一致,本研究表明,随着聚谷氨酰胺长度的增加,聚集倾向增加,并且这种增加与溶剂 - 聚谷氨酰胺相互作用能力的降低相关。这些结果表明,调节溶剂 - 聚谷氨酰胺相互作用可能是治疗聚谷氨酰胺疾病的一种治疗策略。